WCM
HALO icon

Windsor Capital Management’s Halozyme HALO Stock Holding History

Windsor Capital Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-4,000
Closed -$53K – 220
2015
Q3 		$53K Buy
+4,000
New +$80.3K 0.03% 163
2014
Q1 		– Sell
-2,415
Closed -$36K – 161
2013
Q4 		$36K Buy
+2,415
New +$31.1K 0.02% 196

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Windsor Capital Management's HALO Position: Q4 2015 in Review

Windsor Capital Management sold out of Halozyme (HALO) in Q4 2015, closing a stake of 4,000 shares — an estimated $53K sold.

Windsor Capital Management first reported a position in HALO in Q4 2013 and held it in 2 quarters. The position peaked at $53K in Q3 2015. 166 funds tracked by Wall St. Rank hold HALO as of Q4 2015.

  • Windsor Capital Management reported no remaining Halozyme position as of Q4 2015 after selling out during the quarter.
  • Windsor Capital Management sold 4,000 Halozyme shares in Q4 2015, an estimated $53K.
  • Windsor Capital Management first reported a position in Halozyme in Q4 2013 and held it in 2 quarters.
  • Windsor Capital Management's Halozyme position peaked at $53K in Q3 2015.
  • 166 funds tracked by Wall St. Rank held Halozyme as of Q4 2015.

Based on Windsor Capital Management's 13F filing for Q4 2015, filed 1 Feb 2016.